Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (591)	7/7/2004 10:00:25 AM
From: scaram(o)uche	Respond to of 12215

>> or maybe someone is reading the tea leaves on the open label work? << Stock looks sick. Every time I look at it, I also look sick.

To: mopgcw who wrote (591)	7/7/2004 10:31:57 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 12215

forgot to mention..... ARQL.... it's not one of those that I've been nibbling on, recently. :-) :-) BECAUSE I ALREADY HAD TOO DAMN MUCH!! :-(

To: mopgcw who wrote (591)	7/7/2004 10:49:48 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 12215

antibody-dependent cellular cytotoxicity (I can use the "we")...... we've been trying to make it work for twenty years. When, after that period of time, something doesn't work? I usually lose interest. But ADC is different..... IMO it will eventually be THE route to survival, aggressive malignancies. the cell types that bear Fc receptors can be very mean suckers. if we can teach them to do tricks, it will be an enormous step. it may sometimes seem that I'm pessimistic regarding cancer immunology. that's not the case.... I'm just pessimistic about 98% of cancer immunology projects. btw.... too busy to post any longer, pseudobiologist had significant interest and up-to-date knowledge in this area. Rick